AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27863807 — intervention group
Group type: EXPERIMENTAL
Intervention: Switching to adalimumab after non-response to certolizumab pegol
Number of subjects: 915
Study 25009196 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-paravertebral block (PPA)
Number of subjects: 10
Study 25009196 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-opioid (GA)
Number of subjects: 10
Study 22561417 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise group
Number of subjects: 174
Study 22561417 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- to high-intensity exercise group
Number of subjects: 174
Study 22561417 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine physical therapy)
Number of subjects: 174
Study 22561417 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise groups (combined low and moderate-to-high intensity)
Number of subjects: 174
Study 16062003 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based prevention measures for falls and fractures
Number of subjects: 0
Study 12468136 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg DEX tablet
Number of subjects: 298
Study 12468136 — intervention group
Group type: COMPARATOR
Intervention: Intracervical injection of 5 ml mepivacaine 2%
Number of subjects: 298
Study 9659630 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Medicare mammography benefit flier)
Number of subjects: 40
Study 9659630 — intervention group
Group type: EXPERIMENTAL
Intervention: Education (flier and community education program)
Number of subjects: 40
Study 9659630 — intervention group
Group type: EXPERIMENTAL
Intervention: Access (flier, mammography appointments, and transportation)
Number of subjects: 40
Study 9659630 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (all interventions)
Number of subjects: 40
Study 8601046 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrifugal blood pump (group II)
Number of subjects: 120
Study 8601046 — intervention group
Group type: EXPERIMENTAL
Intervention: Roller pump plus aprotinin (group III)
Number of subjects: 120
Study 8601046 — intervention group
Group type: COMPARATOR
Intervention: Roller pump (group I)
Number of subjects: 120
Study 2516361 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate nasal spray
Number of subjects: 0
Study 2516361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) nasal spray
Number of subjects: 0
Study 361144 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 320
Study 361144 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (Control)
Number of subjects: 320
Study 31679747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention with weekly step goals
Number of subjects: 60
Study 31679747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based intervention
Number of subjects: 60
Study 31679747 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 28870846 — intervention group
Group type: EXPERIMENTAL
Intervention: Price increase of 20% on 'red' beverages (nondiet soft drinks, energy drinks)
Number of subjects: 352
Study 28870846 — intervention group
Group type: EXPERIMENTAL
Intervention: Price increase of 20% on 'amber' beverages (diet soft drinks, small pure fruit juices)
Number of subjects: 352
Study 28870846 — intervention group
Group type: EXPERIMENTAL
Intervention: No price change on 'green' beverages (water)
Number of subjects: 352
Study 28870846 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 352
Study 27561175 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal PH94B
Number of subjects: 22
Study 27561175 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 24405979 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (75 mg daily)
Number of subjects: 150
Study 24405979 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low dose aspirin (75 mg daily) and low-molecular-weight heparin
Number of subjects: 150
Study 22584174 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinnacle3 treatment planning system using CCCS algorithm
Number of subjects: 11
Study 20142239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology screening with a cutoff of low-grade squamous intraepithelial lesion or worse
Number of subjects: 1336
Study 20142239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytology screening with original Pap I result
Number of subjects: 1336
Study 20142239 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening laboratory rereading for detecting low-grade lesions or worse as atypical
Number of subjects: 1336
Study 20142239 — intervention group
Group type: EXPERIMENTAL
Intervention: CIN3+ diagnoses in the screened population
Number of subjects: 1336
Study 18206529 — intervention group
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Number of subjects: 27
Study 18206529 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 27
Study 18206529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 16205134 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraPrep solution plus Ioban 2 drapes
Number of subjects: 176
Study 16205134 — intervention group
Group type: COMPARATOR
Intervention: povidone iodine scrub and paint plus Ioban 2 drapes
Number of subjects: 176
Study 12019686 — intervention group
Group type: EXPERIMENTAL
Intervention: Back belts with use instruction
Number of subjects: 12772
Study 12019686 — intervention group
Group type: COMPARATOR
Intervention: Lifting advice only
Number of subjects: 12772
Study 12019686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 12772
Study 10424635 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held computer
Number of subjects: 0
Study 10424635 — intervention group
Group type: COMPARATOR
Intervention: Paper and pencil form
Number of subjects: 0
Study 8636525 — intervention group
Group type: EXPERIMENTAL
Intervention: New double-lumen catheter
Number of subjects: 40
Study 8636525 — intervention group
Group type: COMPARATOR
Intervention: Conventional suctioning
Number of subjects: 40
Study 8636525 — intervention group
Group type: COMPARATOR
Intervention: Conventional endotracheal lavage
Number of subjects: 40
Study 2101781 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral captopril 15 min before thrombolysis (37 patients)
Number of subjects: 72
Study 2101781 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis followed by oral captopril on day 3-4 (35 patients)
Number of subjects: 72
Study 108748 — intervention group
Group type: EXPERIMENTAL
Intervention: (-) trans-delta9-tetrahydrocannabinol (THC) (320 microgram/kg)
Number of subjects: 25
Study 108748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol (0.54 g/kg)
Number of subjects: 25
Study 108748 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of THC and ethanol
Number of subjects: 25
Study 108748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 30421545 — intervention group
Group type: EXPERIMENTAL
Intervention: iGlarLixi
Number of subjects: 0
Study 28449709 — intervention group
Group type: EXPERIMENTAL
Intervention: CME by Case Method
Number of subjects: 460
Study 28449709 — intervention group
Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 460
Study 28449709 — intervention group
Group type: COMPARATOR
Intervention: No CME (reference group)
Number of subjects: 460
Study 25426542 — intervention group
Group type: EXPERIMENTAL
Intervention: Steep Ramp Test (SRT)
Number of subjects: 61
Study 25426542 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary Exercise Test (CPET)
Number of subjects: 61
Study 22884411 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured procedure for setting health (care) priorities
Number of subjects: 317
Study 22884411 — intervention group
Group type: COMPARATOR
Intervention: Standard care by control GPs
Number of subjects: 317
Study 21434338 — intervention group
Group type: EXPERIMENTAL
Intervention: Qutan Huayu Jiedu (QHJ) herbs
Number of subjects: 83
Study 21434338 — intervention group
Group type: COMPARATOR
Intervention: Qutan Huayu (QH) herbs (control)
Number of subjects: 83
Study 19877106 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupational therapy intervention
Number of subjects: 32
Study 19877106 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 32
Study 17993437 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramedullary pinning
Number of subjects: 36
Study 17993437 — intervention group
Group type: COMPARATOR
Intervention: Transverse pinning
Number of subjects: 36
Study 16304443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant applied and reapplied up to 36 months
Number of subjects: 120
Study 16304443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish applied and reapplied up to 42 months
Number of subjects: 120
Study 16304443 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 16304443 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealant group
Number of subjects: 120
Study 16304443 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish group
Number of subjects: 120
Study 11890484 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage intervention (screening and nursing assessment)
Number of subjects: 388
Study 11890484 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 388
Study 9691229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinoylguanidine (PZG), 400 mg three times a day for 3 weeks
Number of subjects: 6
Study 9691229 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazinoylguanidine (PZG)
Number of subjects: 6
Study 9691229 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 7918062 — intervention group
Group type: EXPERIMENTAL
Intervention: rGM-CSF
Number of subjects: 22
Study 7918062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3395403 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadocaine hydrochloride 10 mg
Number of subjects: 40
Study 3395403 — intervention group
Group type: EXPERIMENTAL
Intervention: Vadocaine hydrochloride 30 mg
Number of subjects: 40
Study 3395403 — intervention group
Group type: COMPARATOR
Intervention: Codeine phosphate 50 mg
Number of subjects: 40
Study 3395403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29877169 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-fortified water (ZFW)
Number of subjects: 0
Study 29877169 — intervention group
Group type: COMPARATOR
Intervention: Control group (FW)
Number of subjects: 0
Study 28196256 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic predisposition to increased WHR adjusted for BMI
Number of subjects: 111986
Study 26232170 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-CAP (rituximab, cyclophosphamide, doxorubicin, prednisone with bortezomib)
Number of subjects: 164
Study 26232170 — intervention group
Group type: COMPARATOR
Intervention: R-CHOP (rituximab, cyclophosphamide, doxorubicin, prednisone with vincristine)
Number of subjects: 164
Study 24029854 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonfils Intubation Fiberscope
Number of subjects: 60
Study 24029854 — intervention group
Group type: COMPARATOR
Intervention: McCoy laryngoscope
Number of subjects: 60
Study 21159786 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium citrate (500 mg elemental Mg/d)
Number of subjects: 14
Study 21159786 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18763315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scoring system (CSS) of zygote and embryo morphology
Number of subjects: 117
Study 18763315 — intervention group
Group type: COMPARATOR
Intervention: Cumulative embryo score (CES)
Number of subjects: 117
Study 18763315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scoring system (CSS) for embryos scoring >=70
Number of subjects: 117
Study 18763315 — intervention group
Group type: COMPARATOR
Intervention: Cumulative embryo score (CES) for embryos scoring >=20
Number of subjects: 117
Study 18763315 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined scoring system (CSS) for embryos scoring <70
Number of subjects: 117
Study 17117565 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined regime of auricular-plaster and body acupuncture
Number of subjects: 92
Study 17117565 — intervention group
Group type: COMPARATOR
Intervention: Body acupuncture (control)
Number of subjects: 92
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate antibiotic therapy
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate antibiotic therapy
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiologically confirmed cases
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA grade 3 or more
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Age 64 years or more
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to onset of pneumonia more than 3 days
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Mottling
Number of subjects: 556
Study 12594582 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension
Number of subjects: 556
Study 10930898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.d.s.
Number of subjects: 38
Study 10930898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg b.d. (after 2 weeks of placebo or cisapride 10 mg t.d.s.)
Number of subjects: 38
Study 10930898 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg t.d.s. and 20 mg b.d. (in patients with abnormal baseline electrogastrograms)
Number of subjects: 38
Study 10930898 — intervention group
Group type: COMPARATOR
Intervention: Placebo (for the first 2 weeks)
Number of subjects: 38
Study 8800872 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium ironedetate (Sytron) administered rectally at a concentration of 7.6 mg ml‐1
Number of subjects: 0
Study 1353804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 plus 750 mg/m2 cyclophosphamide (high dose)
Number of subjects: 165
Study 1353804 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m2 plus 750 mg/m2 cyclophosphamide (low dose)
Number of subjects: 165
Study 6615704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast inspiratory flow rate
Number of subjects: 43
Study 6615704 — intervention group
Group type: COMPARATOR
Intervention: Lung volume at the time of aerosol release
Number of subjects: 43
Study 6615704 — intervention group
Group type: COMPARATOR
Intervention: Time interval between the 2 puffs
Number of subjects: 43
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of miR-200c-3p
Number of subjects: 150
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of miR-100-5p
Number of subjects: 150
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma levels of miR-1826
Number of subjects: 150
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-100-5p and DNMT3A mRNA levels
Number of subjects: 150
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-100-5p and ZEB1 mRNA levels
Number of subjects: 150
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-200c-3p and MMP13 mRNA levels
Number of subjects: 150
Study 31860959 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-1826 and CTNNB1 mRNA levels
Number of subjects: 150
Study 29076889 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPS-Family
Number of subjects: 152
Study 29076889 — intervention group
Group type: EXPERIMENTAL
Intervention: TOPS-TO
Number of subjects: 152
Study 29076889 — intervention group
Group type: COMPARATOR
Intervention: IRC
Number of subjects: 152
Study 26716877 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone (400mg/day)
Number of subjects: 46
Study 26716877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24434070 — intervention group
Group type: EXPERIMENTAL
Intervention: Group problem-solving skills training (PST)
Number of subjects: 433
Study 24434070 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 433
Study 24434070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both PST and TAU
Number of subjects: 433
Study 24434070 — intervention group
Group type: EXPERIMENTAL
Intervention: PST
Number of subjects: 433
Study 22820371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (active vitamin D analog compounds); specific dosage and duration not mentioned.
Number of subjects: 0
Study 22820371 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (25‐hydroxy vitamin D); specific dosage and duration not mentioned.
Number of subjects: 0
Study 22820371 — intervention group
Group type: COMPARATOR
Intervention: Randomized control trials of vitamin D; specific dosage and duration not mentioned.
Number of subjects: 0
Study 19782391 — intervention group
Group type: EXPERIMENTAL
Intervention: VST-30 silicone elastomer; polymerised for 20 min; exposed to simulated saliva containing C. albicans for 2h.
Number of subjects: 48
Study 19782391 — intervention group
Group type: EXPERIMENTAL
Intervention: VST-50 silicone elastomer; polymerised for 12h; exposed to simulated saliva containing C. albicans for 2h.
Number of subjects: 48
Study 19782391 — intervention group
Group type: EXPERIMENTAL
Intervention: VST-50F silicone elastomer; polymerised for 6h; exposed to simulated saliva containing C. albicans for 2h.
Number of subjects: 48
Study 19782391 — intervention group
Group type: COMPARATOR
Intervention: Control group; simulated saliva and nasal secretion containing C. albicans.
Number of subjects: 48
Study 17351383 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day)
Number of subjects: 71
Study 17351383 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg/day)
Number of subjects: 71
Study 16351772 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapidly digestible starch
Number of subjects: 10
Study 16351772 — intervention group
Group type: COMPARATOR
Intervention: Slowly digestible starch
Number of subjects: 10
Study 16351772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both starches after 14 d adaptation
Number of subjects: 10
Study 11181473 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin A receptor blocker LU 135252 (30 mg/d)
Number of subjects: 21
Study 11181473 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelin A receptor blocker LU 135252 (300 mg/d)
Number of subjects: 21
Study 11181473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9828759 — intervention group
Group type: COMPARATOR
Intervention: 0 g/200 ml phytic acid (totally dephytinized soya milk)
Number of subjects: 39
Study 9828759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.26 g/200 ml phytic acid (natural phytic acid content)
Number of subjects: 39
Study 9828759 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.13 g/200 ml phytic acid (half dephytinized soya milk)
Number of subjects: 39
Study 8006401 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (2 mg every 6 h)
Number of subjects: 137
Study 8006401 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin (0.4 to 0.8 unit per min) plus transdermal nitroglycerin (20 to 80 mg)
Number of subjects: 137
Study 8006401 — intervention group
Group type: COMPARATOR
Intervention: Vasopressin plus transdermal nitroglycerin
Number of subjects: 137
Study 8006401 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 137
Study 2591221 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous compression-ventilation (SC-V) CPR
Number of subjects: 994
Study 2591221 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPR
Number of subjects: 994
Study 2591221 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 994
Study 4578134 — intervention group
Group type: EXPERIMENTAL
Intervention: Epipodophyllotoxin VP 16213
Number of subjects: 250
Study 429083 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release theophylline capsule, 250 mg every 12 hours
Number of subjects: 18
Study 429083 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Elixophyllin Elixir, 250 mg)
Number of subjects: 18
Study 429083 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoproterenol inhalation
Number of subjects: 18
Study 31438797 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D preoperative planning
Number of subjects: 60
Study 31438797 — intervention group
Group type: COMPARATOR
Intervention: Conventional preoperative planning
Number of subjects: 60
Study 28514458 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle-assisted photodynamic therapy with 20-minute ALA incubation
Number of subjects: 33
Study 28514458 — intervention group
Group type: EXPERIMENTAL
Intervention: Microneedle-assisted photodynamic therapy with 10-minute ALA incubation
Number of subjects: 33
Study 28514458 — intervention group
Group type: COMPARATOR
Intervention: Sham roller (control) with 20-minute ALA incubation
Number of subjects: 33
Study 28514458 — intervention group
Group type: COMPARATOR
Intervention: Sham roller (control) with 10-minute ALA incubation
Number of subjects: 33
Study 26825087 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent detection of BV-associated bacteria (A. vaginae, BVAB1)
Number of subjects: 545
Study 26825087 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial BV-associated bacteria
Number of subjects: 545
Study 26825087 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and/or endometrial positivity for BV-associated bacteria
Number of subjects: 545
Study 26825087 — intervention group
Group type: EXPERIMENTAL
Intervention: Ureaplasmas
Number of subjects: 545
Study 24728104 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperineal ultrasound measurement
Number of subjects: 62
Study 24728104 — intervention group
Group type: COMPARATOR
Intervention: Transvaginal ultrasound measurement
Number of subjects: 62
Study 22111754 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 688336
Study 22111754 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 688336